CClinicalTrials.gg
CompletedNCT05972486Updated Jan 26, 2026Results posted

A Study of MUSE Device for Midlife Women

An interventional study of Muse-S™ headband system in Women's Health, Insomnia and Sleep Disturbance, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to see if it is feasible for midlife women to wear a brain activity sensing headband (Muse-S) for management of sleep disturbances such as insomnia and sleep disruption

02

Conditions studied

  • Women's Health
  • Insomnia
  • Sleep Disturbance
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's enrollment of 31 is below the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Women in the menopause transition or in menopause, based on clinical assessment
  • PSQI score > 5, with overall sleep quality rating of "fairly bad" or "very bad".
  • Motivation VAS score equal to or greater than 5 with overall motivation rating of on a scale of 0-10 with 0 being not motivated at all and 10 being extremely motivated.
  • Access to an iPad, iPhone, or android device.
  • Have ability to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Suspected or untreated obstructive sleep apnea.
  • Moderate to severe vasomotor symptoms warranting prescription medication use. The FDA categories for hot flash severity are classified as mild (sensation of heat without sweating), moderate (sensation of heat with sweating, able to continue activity), or severe (sensation of heat with sweating cause cessation of activity).
  • Use of hormone therapy or hypnotic agents.
  • Use of supplements known to affect sleep.
  • A known, active, untreated clinically significant psychiatric condition.
  • Use of an investigational drug within 30 days of study enrollment or presence of a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
  • Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Muse-S headband system for management of sleep disturbances

    Study participants will receive a new Muse-S headband system at study entry and will be asked to utilize it daily for a minimum of 10 minutes day for a period of 6 months (24 weeks). Three of the seven sessions per week will specifically be asked to be mind meditation.

    Device: Muse-S™ headband system

Interventions

  • DeviceMuse-S™ headband system

    Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.

06

What researchers measure

Primary outcomes

  1. Change in Quality of Sleep

    Measured using the self-reported Pittsburgh Sleep Quality Index (PSQI) to assess the severity of sleep disturbances. Possible scores range from 0 to 21 with higher scores indicating a worse outcome/more severe symptoms of sleep disturbance.

    Time frame: Baseline, 3 months, 6 months

  2. Sleep Impact

    Measured using the self-reported ASCQ-Me Sleep Impact Short Form. The 5-item questionnaire used to assess functioning and wellbeing in accordance with sleep. The questions in this assessment tool ask how often they felt sleep impacted specific activities during the the past 7 days. Possible answers include: 5 - never; 4 - rarely; 3 - sometimes; 2 - often, and 1 - always. Possible scores range from 5 to 25, with higher scores indicating a better outcome.

    Time frame: Baseline, 3 months, 6 months

Secondary outcomes

  1. Perceived Stress Levels

    Measured using the self-reported Perceived Stress Scale (PSS). The 10-item questionnaire measures global perceived stress experienced by the participant over the preceding 30 days. The questions in this assessment tool ask how often the participant felt or thought a certain way during the past month. Possible answers include: 0 - never; 1 - almost never; 2 - sometimes; 3 - fairly often, and 4 - very often. Possible scores range from 0 to 40, with lower scores indicating a better outcome (less stress).

    Time frame: Baseline, 3 months, 6 months

  2. Change in Perceived Anxiety

    Measured using the self-reported Generalized Anxiety Disorder Scale (GAD-7). The 7-item questionnaire assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety. With higher scores indicating more severe anxiety.

    Time frame: Baseline, 3 months, 6 months

  3. Sexual Function

    Measured using the self-reported Female Sexual Function Index (FSFI). The 19-item questionnaire to assess the sexual functioning in women. The questions in this assessment tool ask participants about a specific sexual function within the past 4 weeks on a Likert scale range of 0-5. Total scores range from 2 to 36, with lower scores indicating worse sexual functioning.

    Time frame: Baseline, 3 months, 6 months

  4. Sexual Distress

    Measured using the Female Sexual Distress Scale (FSDS-R). The 13-item questionnaire to assess sexually related personal distress over the pas 30 days. The questions in this assessment tool asks how often the participant felt during the past month. Possible answers include: 0 - never; 1 - rarely; 2 - occasionally; 3 - frequently, and 4 - always. Possible scores range from 0 to 60, with higher scores indicating greater level of distress.

    Time frame: Baseline, 3 months, 6 months

  5. Change in Quality of Life

    Measured using the self-reported Patient Health Questionnaire (PHQ-9). The 9-item questionnaire used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression. With higher scores indicating more severe depression.

    Time frame: Baseline, 3 months, 6 months

07

Results

Posted Jan 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneMuse-S Headband System for Management of Sleep Disturbances
Started31
Completed14
Not completed17
Withdrew: Withdrawal by subject17

Outcome measures

PrimaryChange in Quality of Sleep

Measured using the self-reported Pittsburgh Sleep Quality Index (PSQI) to assess the severity of sleep disturbances. Possible scores range from 0 to 21 with higher scores indicating a worse outcome/more severe symptoms of sleep disturbance.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · score on a scale
Change in Quality of Sleep
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline to 3 Months-3 (-4 to -2)
Baseline to 6 Months-4 (-9 to -3)
3 Months to 6 Months-1 (-3 to 0)
PrimarySleep Impact

Measured using the self-reported ASCQ-Me Sleep Impact Short Form. The 5-item questionnaire used to assess functioning and wellbeing in accordance with sleep. The questions in this assessment tool ask how often they felt sleep impacted specific activities during the the past 7 days. Possible answers include: 5 - never; 4 - rarely; 3 - sometimes; 2 - often, and 1 - always. Possible scores range from 5 to 25, with higher scores indicating a better outcome.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Sleep Impact
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline18 (8 to 25)
3 Months22 (14 to 25)
6 Months23 (14 to 25)
SecondaryPerceived Stress Levels

Measured using the self-reported Perceived Stress Scale (PSS). The 10-item questionnaire measures global perceived stress experienced by the participant over the preceding 30 days. The questions in this assessment tool ask how often the participant felt or thought a certain way during the past month. Possible answers include: 0 - never; 1 - almost never; 2 - sometimes; 3 - fairly often, and 4 - very often. Possible scores range from 0 to 40, with lower scores indicating a better outcome (less stress).

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Perceived Stress Levels
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline16 (1 to 27)
3 Months12 (2 to 21)
6 Months12 (4 to 22)
SecondaryChange in Perceived Anxiety

Measured using the self-reported Generalized Anxiety Disorder Scale (GAD-7). The 7-item questionnaire assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety. With higher scores indicating more severe anxiety.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Change in Perceived Anxiety
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline to 3 Months-2 (-3 to -1)
Baseline to 6 Months-2 (-4 to 0)
3 Months to 6 Months0 (-5 to 3)
SecondarySexual Function

Measured using the self-reported Female Sexual Function Index (FSFI). The 19-item questionnaire to assess the sexual functioning in women. The questions in this assessment tool ask participants about a specific sexual function within the past 4 weeks on a Likert scale range of 0-5. Total scores range from 2 to 36, with lower scores indicating worse sexual functioning.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Sexual Function
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline18 (2 to 34)
3 Months18 (4 to 34)
6 Months21 (3 to 33)
SecondarySexual Distress

Measured using the Female Sexual Distress Scale (FSDS-R). The 13-item questionnaire to assess sexually related personal distress over the pas 30 days. The questions in this assessment tool asks how often the participant felt during the past month. Possible answers include: 0 - never; 1 - rarely; 2 - occasionally; 3 - frequently, and 4 - always. Possible scores range from 0 to 60, with higher scores indicating greater level of distress.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Sexual Distress
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline23.5 (13 to 53)
3 Months24 (13 to 50)
6 Months18 (12 to 41)
SecondaryChange in Quality of Life

Measured using the self-reported Patient Health Questionnaire (PHQ-9). The 9-item questionnaire used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression. With higher scores indicating more severe depression.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Median · score on a scale
Change in Quality of Life
score on a scaleMuse-S Headband System for Management of Sleep Disturbances
Baseline to 3 Months-2 (-3 to -1)
Baseline to 6 Months-2 (-3 to -1)
3 Months to 6 Months0 (-3 to 1)

Adverse events

Collected over Adverse events were collected from the time of informed consent through study completion, approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Muse-S Headband System for Management of Sleep Disturbances0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Muse-S Headband System for Management of Sleep Disturbances
<=18 years0
Between 18 and 65 years31
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Muse-S Headband System for Management of Sleep Disturbances
Female31
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Muse-S Headband System for Management of Sleep Disturbances
Hispanic or Latino0
Not Hispanic or Latino31
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Muse-S Headband System for Management of Sleep Disturbances
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White29
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Muse-S Headband System for Management of Sleep Disturbances
United States31
08

Study locations

1 site
  • Mayo Clinic Minnesota
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 31, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05972486
Lead sponsor
Mayo Clinic
Responsible party
Amber L. Klindworth (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 2, 2023
Start date
Aug 1, 2023
Primary completion
Jan 12, 2025
Completion
Jan 12, 2025
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Study contacts

Amber Klindworth, PA-C
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion